Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings.

ABSTRACT:

Lessons learned

The combination of the antivascular endothelial growth factor receptor 2 monoclonal antibody, ramucirumab, and the type II MET kinase inhibitor, merestinib, is tolerable. Preliminary efficacy data suggest that the combination may provide clinical benefit to patients with metastatic colorectal cancer (mCRC). Further development of this combination would likely necessitate the identification of subsets of patients with mCRC where the clinical benefit is of clinical relevance.

Background

This study evaluated safety, preliminary efficacy, and pharmacokinetics of ramucirumab plus merestinib in patients with MCR previously treated with oxaliplatin and/or irinotecan.

Methods

Open-label phase Ia/b study comprising 3+3 dose-limiting toxicity (DLT) observation a

SUBMITTER: Saleh M 

PROVIDER: S-EPMC7648328 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature